MSMarina P. Smirnova

Marina P. Smirnova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marina P. Smirnova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Markers of myocardial stress, fibrosis and inflammation in patients with chronic heart failure of different phenotypes and their relationship with echocardiography parameters

    by Darya A. Korsakova, Petr A. Chizhov, Marina P. Smirnova, Marina A. Pegashova

    BACKGROUND: A generally accepted marker for confirming the diagnosis of acute and chronic heart failure (CHF) and risk stratification in such patients is the level of N-terminal pro-B-type natriuretic peptide (NT-proBNP). In recent years, such biomarkers of myocardial fibrosis and remodeling as soluble suppressor of tumorigenicity 2 (sST2) and galectin-3, which have prognostic value, have been actively studied in patients with CHF. Considering the role of chronic inflammation in the pathogenesis of CHF, of interest is the assessment of the level of high-sensitivity C-reactive protein (hsCRP), which is a marker of inflammation. However, the characteristics of changes in these markers in patients with different phenotypes of CHF remain poorly understood in their comprehensive examination; the relationship between these indicators and echocardiography parameters (ECHO-CG) has not been studied. AIM: To evaluate the levels of sST2, galectin-3, NT-proBNP and hsСRP in the blood of patients with CHF of different phenotypes and their relationship with ECHO-CG parameters. METHODS: A total of 102 patients (72 women and 30 men, mean age 74.3 ± 9.1 years) hospitalized with decompensated CHF with the underlying grade II–III essential hypertension and/or II–III functional class exertion angina, were examined. Based on ECHO-CG results, the subjects were divided into 2 groups depending on the left ventricular (LV) ejection fraction (EF): group 1 — patients with preserved LVEF, group 2 — patients with moderately reduced and low LVEF. In all subjects, NT-proBNP, hsСRP, sST2 and galectin-3 levels were determined. RESULTS: In patients with CHF of group 2 sST2 and NT-proBNP levels were higher than in patients with CHF in group 1. Elevated sST2 concentration is associated with greater diameter of the aorta, LV end systolic dimension, right ventricle size, pulmonary artery systolic pressure (PASP) and lower LVEF. A ≥ 2-fold increase in NT-proBNP levels is associated with increased size of atria, PASP, pulmonary artery occlusion pressure, and decreased LVEF. A hsCRP level 5 mg/l is associated with increased PASP and pulmonary artery occlusion pressure. CONCLUSION: The progression of CHF is accompanied by an increase in sST2 and NT-proBNP, however, despite similar correlations with ECHO-CG parameters and supposed unidirectional action of markers in the development of the disease, there are differences, which in more detail reflect pathogenetic participation of molecules in CHF progression.

  • Paroxysmal atrial fibrillation in patients with sinoatrial blockade undergoing permanent pacing and metabolic therapy

    by V.N. Smirnov, I.N. Staroverov, G.A. Gromyko, M.P. Smirnova

    Objective. To study the effect of trimetazidine dihydrochloride on the total number of atrial fibrillation paroxysms in patients with sinus node weakness syndrome and permanent two-chamber pacing. Material and methods. The study included 138 patients with various types of sinoatrial blockades and two-chamber pacing systems. Two groups of patients were formed: 1 — patients receiving metabolic therapy; 2 — patients not receiving metabolic therapy. The effect of trimetazidine dihydrochloride on the total number of atrial fibrillation paroxysms was evaluated in 3 and 12 months after implantation of two-chamber pacing system. All patients of both groups received standard therapy for concomitant diseases. Results. Trimetazidine dihydrochloride in patients with various types of sinoatrial blockades after implantation of two-chamber pacing system reduces the total number of paroxysms of atrial fibrillation. There was a significant (p<0.05) decrease in the number of paroxysms of atrial fibrillation under metabolic therapy in 3 and 12 months after pacing system implantation. Conclusion. Administration of trimethazidine dihydrochloride as a part of complex therapy reduces the total number of paroxysms of atrial fibrillation in patients with sinus node weakness syndrome after implantation of two-chamber pacing system.

  • Open Access

    Prevalence and severity of chronic kidney disease in a therapeutic hospital in patients with hypertension, angina pectoris, and type 2 diabetes mellitus: real practice of treating

    by M. A. Pegashova, P. A. Chizhov, M. P. Smirnova, T. V. Medvedeva, M. I. Кorkina

    Relevance. Chronic kidney disease (CKD) develops in the context of many diseases and has a progressive course, with the outcome of chronic renal failure.Objective. To study the prevalence and severity of CKD in patients of the therapeutic department with hypertension, coronary heart disease (CHD) by type of angina 2-3 FC (NYHA), type 2 diabetes mellitus (T2DM) and their combinations, as well as the real practice of therapy of such patients.Materials and methods. A total of 193 patients (average age 64.0 ± 18.1 with hypertension, CHD, T2DM, and their combinations were examined and treated in the therapeutic department of the N.A. Semashko City Hospital in the Yaroslavl Region was closed due to deterioration of their condition. The glomerular filtration rate (GFR) was calculated using the CKD-EPI formula. Statistical processing of the results was performed using the Statistica 12.0 program (StatSoft. Inc., USA).Results. CKD stage 1 was diagnosed in 4.3% of the examined patients, stage 2 in 18.2%, stage 3 in 42.6%, and stage 4 in 2.9%. CKD stages 1 and 2 were significantly more common in patients with isolated hypertension, compared with those examined with hypertension + coronary heart disease + T2DM (p = 0.01, p = 0.03, respectively). CKD stage 3 was diagnosed in 100% of patients with T2DM + coronary heart disease. In patients with stage 3 hypertension and 3 FC CHF (NYHA), obesity, the GFR was significantly lower in men than in patients with stage 1 and 2 hypertension, with 2 FC CHF, no obesity, and women. Correlations of GFR with age and duration of hypertension and T2DM were established. The shortcomings of pharmacotherapy of patients with CKD in the hospital were revealed: no one receives IDPP-4 and gliflozins, some patients with low SCF receive metformin, some do not receive angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, statins, and some patients with type 2 diabetes did not undergo proper titration of the dose of hypoglycemic drugs.Conclusions. CKD stages 1–4 were detected in 68% of patients with hypertension, coronary heart disease, and/or type 2 diabetes in the therapeutic hospital, of which 42.6% had stage 3 and 2.9% had stage 4. The GFR value was associated with the degree of hypertension, FC CHF (NYHA), obesity, sex, age, hypertension duration, and type 2 diabetes. In hospitals, recommendations for pharmacotherapy for patients with CKD are not always followed.

  • Open Access

    Factors associated with iron deficiency in heart failure

    by M. P. Smirnova, P. A. Chizhov

    Aim. To establish the factors associated with iron deficiency (ID) in pa- tients with heart failure (HF).Material and methods. We examined 294 patients with NYHA class II-IV HF as follows: 213 — with ID, 81 — without ID. All patients underwent a clinical examination, collection of medical history taking into account the presence, duration and severity of comorbidities, drug history, echocardiography, complete blood count, serum iron, ferritin, transferrin, transferrin saturation, soluble transferrin receptors, hepcidin, erythropoietin, and routine laboratory tests. In addition, we determined the presence and severity of asthenia, anxiety, and depression.Results. Twenty-nine clinical, laboratory and echocardiographic parameters were established, which had significant differences in patients with and without ID and significant correlations with ID. Determining the odds ratio for these 29 parameters revealed 7 factors significantly associated with ID in patients with HF. Using multivariate logistic regression, a significant cumulative effect of these factors on the ID risk was established.Conclusion. ID in patients with HF is associated with age, class II-IV HF, elevated hepcidin levels, duration of hypertension and diabetes, history of using angiotensin-converting enzyme inhibitors and novel oral anticoagulants for >1 year.


  • Open Access

    Characteristics of clinical and laboratory parameters in patients with chronic heart failure of elderly and senile age with iron deficiency

    by M. P. Smirnova, P. A. Chizhov, D. A. Korsakova, A. A. Baranov

    Relevance.The frequency of chronic heart failure (CHF) increases with age. A common pathology in patients with CHF is iron deficiency (ID). Age may contribute to development of ID in patients with CHF.The purpose of the study:To study the features of clinical and laboratory parameters in elderly and senile patients with CHF, depending on the presence of ID.Materials and methods:2 groups of patients with CHF 2-4 functional class were examined: group 1-60-74 years (146 patients, mean age 68.1±3.1), group 2-75 years and older (127 patients, mean age 78.3±2.2). All patients underwent a clinical examination, a 6-minute walk test, a general blood test, the determination of the level of iron, ferritin, transferrin in blood serum, iron saturation of transferrin, soluble transferrin receptors, hepcidin, interleukin-6, C-reactive protein, the presence and severity of asthenia, anxiety, depression.Results.It has been established that patients in the senile group have a significantly higher functional life expectancy and more pronounced clinical and laboratory manifestations of CHF (the worst 6-minute walk test, more pronounced manifestations of asthenia and depression, a higher concentration of NT-proBNP, hepcidin), compared with elderly patients. The presence of ID in both age groups increases the manifestations of physical asthenia and anxiety.Conclusions:1) the severity of clinical manifestations of CHF in senile patients is significantly higher than in elderly patients; 2) in senile patients, the levels of hepcidin and latent ID are significantly higher than those in elderly patients; 3) latent ID in both age groups increases the manifestations of physical asthenia and anxiety; 4) it is advisable to conduct early diagnosis of latent ID in all patients with CHF of elderly and, especially, senile age for the timely detection of this condition and the appointment of therapy for correcting ID.


  • Open Access

    Depression, anxiety and asthenia in patients with comorbidity of chronic heart failure and iron deficiency

    by Marina P. Smirnova, Petr A. Chizhov, Andrey A. Baranov

    BACKGROUND: A common comorbid pathology in patients with chronic heart failure is iron deficiency, as well as depressive and anxiety disorders. AIM: To study the frequency and severity of depression, anxiety and asthenia in patients with heart failure and iron deficiency. MATERIALS AND METHODS: 290 patients, 78 men and 212 women (mean age 71.29 8.11 years) with chronic heart failure, functional class IIIV, have been examined. All the patients underwent clinical examination, a 6-minute walk test; a general blood test, the level of NT-proBNP, iron, transferrin, and ferritin in blood serum have been studied; the percentage of transferrin saturation with iron has been calculated. The presence of iron deficiency has been diagnosed on the basis of the following criteria: a decrease in the level of serum ferritin (less than 100 g/L) or ferritin in the range from 100 to 299 g/L and saturation of transferrin with iron less than 20 %. Hospital anxiety and depression scale (HADS) has been used to determine the presence and severity of depression and anxiety in points; the presence and severity of asthenia have been evaluated according to MFI-20 asthenia scale. RESULTS: It has been found that in patients with chronic heart failure and iron deficiency, depression and anxiety are diagnosed significantly more often than in patients without iron deficiency. In addition, in patients with iron deficiency, the severity of depression, anxiety and various manifestations of asthenia are significantly greater. CONCLUSIONS: In chronic heart failure, iron deficiency predisposes patients to the development of depression and anxiety and an increase in various manifestations of asthenia.

  • Open Access

    Parameters of intracardiac hemodynamics in iron deficiency in patients with chronic heart failure

    by Marina P. Smirnova, Petr A. Chizhov, Andrey A. Baranov, Yuliya I. Ivanova

    BACKGROUND: Iron deficiency is a common comorbidity in many patients with chronic heart failure. AIM: To study the parameters of intracardiac hemodynamics in the patients with chronic heart failure in the presence of iron deficiency. MATERIALS AND METHODS: We examined 179 patients (36 men and 143 women, mean age 71.6 7.9 years) with heart failure of functional class 2-4 (NYHA). All the patients underwent a clinical examination, a 6-minute walk test, a general blood test; the level of NT-proBNP, iron, transferrin, and ferritin in blood serum were studied; the percentage of transferrin saturation with iron was calculated. The presence of iron deficiency was assessed based on a decrease in the level of serum ferritin less than 100 g/L or ferritin ranging from 100 to 299 g/L and saturation of transferrin with iron less than 20%. All the patients underwent echocardiography in one-dimensional, two-dimensional and Doppler modes (pulse-wave, constant-wave and tissue) in standard positions according to the generally accepted technique. RESULTS: It was found that in the patients with chronic heart failure and iron deficiency compared with the patients without iron deficiency; the end systolic volume of the left ventricle, the size of the right ventricle and the systolic pressure in the pulmonary artery were significantly higher, and the speed of movement of the fibrous ring of the mitral and tricuspid valves and the working capacity were lower. Significant correlations were established between the concentration of iron and ferritin and the parameters of intracardiac hemodynamics. CONCLUSIONS: Iron deficiency in the patients with chronic heart failure without anemia contributes to an early initial decrease in cardiac contractility with an intact ejection fraction.